Use of teduglutide in adults with short bowel syndrome–associated intestinal failure
Nutrition in Clinical Practice · 2024
DOI: 10.1002/ncp.11015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition in Clinical Practice, 2024. Verfasst von Loris Pironi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Intestinal Failure, Peptides. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals International AG, Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS‐IF) and poor health‐related outcomes. Patients with SBS‐IF are unable to absorb sufficient nutrients or fluids to maintain significantly metabolic homeostasis via oral or enteral intake alone and require long‐term intravenous supplementation (IVS), consisting of partial or total parenteral nutrition, fluids, electrolytes, or a combination of these. The goal of medical and surgical treatment for patients with SBS‐IF is to maximize intestinal remnant absorptive capacity so that the need for IVS support may eventually be reduced or eliminated. Daily subcutaneous administration of the glucagon‐like peptide 2 analog, teduglutide, has been shown to be clinically effective in reducing IVS dependence and potentially improving the health‐related quality of life of patients with SBS‐IF. The management of patients with SBS‐IF is complex and requires close monitoring. This narrative review discusses the use of teduglutide for patients with SBS‐IF in clinical practice. The screening of patient eligibility for teduglutide treatment, initiation, monitoring of efficacy and safety of treatment, adapting or weaning off IVS, and the healthcare setting needed for SBS‐IF management are described, taking into consideration data from clinical trials, observational studies, and clinical experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Centre for Chronic Intestinal Failure-Clinical Nutrition and Metabolism Unit, IRCCS AOUBO, Bologna, Italy.
- Division of Gastroenterology, Department of Medicine, Toronto General Hospital, Toronto, ON, Canada.
- Service de Gastro-entérologie, MICI et Assistance Nutritive, Université de Paris, Hôpital Beaujon, Centre de Référence des Maladies Digestives Rares, Assistance Publique-Hôpitaux de Paris, Clichy, France.
- Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, Hamburg, Germany.
Förderung
- Takeda Pharmaceuticals International AG
- Takeda Pharmaceutical Company
Zitieren
APA
Pironi, L., Allard, J. P., Joly, F., Geransar, P., Genestin, E., & Pape, U. F. (2024). Use of teduglutide in adults with short bowel syndrome–associated intestinal failure. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.11015
Vancouver
Pironi L, Allard JP, Joly F, Geransar P, Genestin E, Pape UF. Use of teduglutide in adults with short bowel syndrome–associated intestinal failure. Nutrition in Clinical Practice. 2024. doi:10.1002/ncp.11015
BibTeX
@article{Pironi2024,
author = {Pironi, Loris and Allard, Johane P and Joly, Francisca and Geransar, Parnia and Genestin, Elisabeth and Pape, Ulrich-Frank},
title = {Use of teduglutide in adults with short bowel syndrome–associated intestinal failure},
journal = {Nutrition in Clinical Practice},
year = {2024},
doi = {10.1002/ncp.11015}
}
EUVIMED